Literature DB >> 17599429

Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.

Mark D Sullivan1, Roger T Anderson, David Aron, Hal H Atkinson, Arnaud Bastien, G John Chen, Patricia Feeney, Amiram Gafni, Wenke Hwang, Lois A Katz, K M Narayan, Chuke Nwachuku, Patrick J O'Connor, Ping Zhang.   

Abstract

Diabetes mellitus affects not only life expectancy but also quality of life. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial's health-related quality of life (HRQOL) and cost-effectiveness components will enable the assessment of the relative importance of the various outcomes from the point of view of patients, provide an understanding of the balance between the burdens and benefits of the intervention strategies, and offer valuable insights into adherence. The HRQOL measures used include the Diabetes Symptoms Distress Checklist; the 36-Item Short Form Health Survey, Version 2 (SF-36) (RAND Corporation, Santa Monica, CA); the Patient Health Questionnaire (PHQ) depression measure (Pfizer Inc, New York, NY); the World Health Organization (WHO) Diabetes Treatment Satisfaction Questionnaire (DTSQ); and the EuroQol Feeling Thermometer (EuroQol Group, Rotterdam, Netherlands). The cost-effectiveness analysis (CEA) in ACCORD will provide information about the relative economic efficiency of the different interventions being compared in the trial. Effectiveness will be measured in terms of cardiovascular event-free years gained and quality-adjusted life-years gained (using the Health Utilities Index Mark 3 [HUI-3] [Health Utilities Inc., Dundas, Ontario, Canada] to measure health-state utility). Costs will be direct medical costs assessed from the perspective of a single-payer health system collected by means of patient and clinic cost forms and hospital discharge summaries. The primary HRQOL and CEA hypotheses mirror those in the main ACCORD trial, addressing the effects of the 3 main ACCORD interventions considered separately. There are also secondary (pairwise reference case) comparisons that do not assume independence of treatment effects on HRQOL. CEA will be done on a subsample of 4,311 ACCORD participants and HRQOL on a subsample of 2,053 nested within the CEA subsample. Most assessments will occur through questionnaires at baseline and at 12, 36, and 48 months.

Entities:  

Mesh:

Year:  2007        PMID: 17599429     DOI: 10.1016/j.amjcard.2007.03.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Blood pressure control for diabetic retinopathy.

Authors:  Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank
Journal:  Cochrane Database Syst Rev       Date:  2015-01-31

2.  Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.

Authors:  Hui Shao; Shuang Yang; Vivian Fonseca; Charles Stoecker; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 3.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

4.  The role of the electronic medical record in the assessment of health related quality of life.

Authors:  Serguei V S Pakhomov; Nilay D Shah; Holly K Van Houten; Penny L Hanson; Steven A Smith
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

5.  Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy.

Authors:  Mark D Sullivan; Patrick O'Connor; Patricia Feeney; Don Hire; Debra L Simmons; Dennis W Raisch; Lawrence J Fine; K M Venkat Narayan; Mohammad K Ali; Wayne J Katon
Journal:  Diabetes Care       Date:  2012-05-22       Impact factor: 19.112

6.  The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial.

Authors:  Annie LeBlanc; Kari L Ruud; Megan E Branda; Kristina Tiedje; Kasey R Boehmer; Laurie J Pencille; Holly Van Houten; Marc Matthews; Nilay D Shah; Carl R May; Barbara P Yawn; Victor M Montori
Journal:  BMC Health Serv Res       Date:  2012-05-28       Impact factor: 2.655

7.  Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial.

Authors:  Roger T Anderson; K M Venkat Narayan; Patricia Feeney; David Goff; Mohammed K Ali; Debra L Simmons; Jo-Ann Sperl-Hillen; Thomas Bigger; Robert Cuddihy; Patrick J O'Conner; Ajay Sood; Ping Zhang; Mark D Sullivan
Journal:  Diabetes Care       Date:  2011-02-23       Impact factor: 19.112

8.  Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.

Authors:  Dennis W Raisch; Patricia Feeney; David C Goff; K M Venkat Narayan; Patrick J O'Connor; Ping Zhang; Don G Hire; Mark D Sullivan
Journal:  Cardiovasc Diabetol       Date:  2012-07-11       Impact factor: 9.951

9.  Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial.

Authors:  Patrick J O'Connor; K M Venkat Narayan; Roger Anderson; Patricia Feeney; Larry Fine; Mohammed K Ali; Debra L Simmons; Don G Hire; JoAnn M Sperl-Hillen; Lois Anne Katz; Karen L Margolis; Mark D Sullivan
Journal:  Diabetes Care       Date:  2012-05-14       Impact factor: 19.112

Review 10.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.